Literature DB >> 22001577

Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.

Christopher P Sullivan1, Eric A Berg, Rosemary Elliott-Bryant, Jordan B Fishman, Ann C McKee, Peter J Morin, Michael A Shia, Richard E Fine.   

Abstract

N-terminal truncated amyloid beta (Aβ) derivatives, especially the forms having pyroglutamate at the 3 position (AβpE3) or at the 11 position (AβpE11) have become the topic of considerable study. AβpE3 is known to make up a substantial portion of the Aβ species in senile plaques while AβpE11 has received less attention. We have generated very specific polyclonal antibodies against both species. Each antibody recognizes only the antigen against which it was generated on Western blots and neither recognizes full length Aβ. Both anti-AβpE3 and anti-AβpE11 stain senile plaques specifically in Alzheimer's disease cerebral cortex and colocalize with Aβ, as shown by confocal microscopy. In a majority of plaques examined, AβpE11 was observed to be the dominant form in the innermost core. These data suggest that AβpE11 may serve as a generating site for senile plaque formation. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001577      PMCID: PMC3253715          DOI: 10.1016/j.neulet.2011.09.071

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  22 in total

1.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.

Authors:  C J Pike; M J Overman; C W Cotman
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

2.  On the seeding and oligomerization of pGlu-amyloid peptides (in vitro).

Authors:  Stephan Schilling; Thomas Lauber; Michael Schaupp; Susanne Manhart; Eike Scheel; Gerald Böhm; Hans-Ulrich Demuth
Journal:  Biochemistry       Date:  2006-10-17       Impact factor: 3.162

3.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

4.  Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.

Authors:  Kangning Liu; Ingrid Solano; David Mann; Cynthia Lemere; Marc Mercken; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2006-06-01       Impact factor: 17.088

5.  beta-amyloid is different in normal aging and in Alzheimer disease.

Authors:  Alessandra Piccini; Claudio Russo; Alessandra Gliozzi; Annalisa Relini; Antonella Vitali; Roberta Borghi; Luca Giliberto; Andrea Armirotti; Cristina D'Arrigo; Angela Bachi; Angela Cattaneo; Claudio Canale; Silvia Torrassa; Takaomi C Saido; William Markesbery; Pierluigi Gambetti; Massimo Tabaton
Journal:  J Biol Chem       Date:  2005-08-15       Impact factor: 5.157

6.  Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.

Authors:  Holger Cynis; Eike Scheel; Takaomi C Saido; Stephan Schilling; Hans-Ulrich Demuth
Journal:  Biochemistry       Date:  2008-06-21       Impact factor: 3.162

7.  Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.

Authors:  H Mori; K Takio; M Ogawara; D J Selkoe
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

8.  Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

Authors:  T C Saido; T Iwatsubo; D M Mann; H Shimada; Y Ihara; S Kawashima
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

Review 9.  Trisomy 21 and the brain.

Authors:  Robert E Mrak; W Sue T Griffin
Journal:  J Neuropathol Exp Neurol       Date:  2004-07       Impact factor: 3.685

10.  Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.

Authors:  Maike Hartlage-Rübsamen; Markus Morawski; Alexander Waniek; Carsten Jäger; Ulrike Zeitschel; Birgit Koch; Holger Cynis; Stephan Schilling; Reinhard Schliebs; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2011-02-08       Impact factor: 17.088

View more
  17 in total

1.  Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.

Authors:  Violetta N Pivtoraiko; Eric E Abrahamson; Sue E Leurgans; Steven T DeKosky; Elliott J Mufson; Milos D Ikonomovic
Journal:  Neurobiol Aging       Date:  2014-06-24       Impact factor: 4.673

2.  Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Authors:  Adam P Gunn; Bruce X Wong; Timothy Johanssen; James C Griffith; Colin L Masters; Ashley I Bush; Kevin J Barnham; James A Duce; Robert A Cherny
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

3.  A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.

Authors:  Valérie Vingtdeux; Haitian Zhao; Pallavi Chandakkar; Christopher M Acker; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2016-11-28       Impact factor: 6.354

4.  Truncated Amyloid-β(11-40/42) from Alzheimer Disease Binds Cu2+ with a Femtomolar Affinity and Influences Fiber Assembly.

Authors:  Joseph D Barritt; John H Viles
Journal:  J Biol Chem       Date:  2015-09-25       Impact factor: 5.157

5.  Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Authors:  Jeffrey L Frost; Kevin X Le; Holger Cynis; Elizabeth Ekpo; Martin Kleinschmidt; Roberta M Palmour; Frank R Ervin; Shikha Snigdha; Carl W Cotman; Takaomi C Saido; Robert J Vassar; Peter St George-Hyslop; Tsuneya Ikezu; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Am J Pathol       Date:  2013-06-07       Impact factor: 4.307

6.  Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation.

Authors:  Rashmi Adhikari; Mu Yang; Nabanita Saikia; Colina Dutta; Wafa F A Alharbi; Zhiying Shan; Ravindra Pandey; Ashutosh Tiwari
Journal:  ACS Chem Neurosci       Date:  2020-04-02       Impact factor: 4.418

7.  An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Authors:  Jeffrey L Frost; Bin Liu; Jens-Ulrich Rahfeld; Martin Kleinschmidt; Brian O'Nuallain; Kevin X Le; Inge Lues; Barbara J Caldarone; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Neurobiol Aging       Date:  2015-08-31       Impact factor: 4.673

8.  Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy.

Authors:  Christina Dammers; Lothar Gremer; Philipp Neudecker; Hans-Ulrich Demuth; Melanie Schwarten; Dieter Willbold
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

9.  Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.

Authors:  Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363

10.  Cu(II) binding to various forms of amyloid-β peptides. Are they friends or foes?

Authors:  Valentina Borghesani; Bruno Alies; Christelle Hureau
Journal:  Eur J Inorg Chem       Date:  2018-01-10       Impact factor: 2.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.